Investment Rating - The report recommends several companies in the retail sector, including leading brands in various categories such as children's retail, beauty, medical aesthetics, and jewelry [5][6]. Core Insights - The report highlights the ongoing transformation of the company, focusing on quality retail and optimizing store operations to better match consumer demand in Changsha, where the consumer base is young and economically active [4][5][30]. - The company has undergone significant restructuring, reducing the number of its supermarkets from 343 to 96 and its department stores from 43 to 37 between 2021 and 2023, aiming to streamline operations and focus on core areas [3][12][17]. - The introduction of a new management team from a successful competitor has led to impressive sales growth in restructured stores, with some locations reporting sales increases of over 300% during peak periods [5][51]. Summary by Sections 1. Background and Progress of Restructuring - The company has faced continuous operational pressure since 2021, leading to a strategic overhaul that includes closing underperforming stores and focusing on core business areas [3][11][17]. - The restructuring process has been supported by a new management team, which is implementing comprehensive changes across various operational aspects [18][19]. 2. Consumer Structure and Characteristics in Changsha - Changsha's GDP has shown steady growth, with a projected increase of over 5.5% in 2025, indicating a robust economic environment for retail [30][31]. - The demographic profile of Changsha is notably young, with nearly 50% of the population aged 18-24, which drives demand for differentiated products and services [4][39]. 3. Performance of Reformed Stores - The report details the successful transformation of several stores, with significant increases in sales and customer traffic post-restructuring [5][51][58]. - Specific stores have reported remarkable sales figures, with daily sales reaching as high as 240.22 million yuan during peak periods [51]. 4. Key Company Financial Forecasts and Valuations - The report provides earnings per share (EPS) forecasts and price-to-earnings (PE) ratios for various recommended companies, indicating strong growth potential in the retail sector [6].

人工智能突破降本提效，服务业 智能体涌现应用场景 核心观点 我们认为本轮 DeepSeek 取得的突破预示着人工智能进入算法优 化阶段并且可能迎接 AI 的摩尔定律时代，应用 AI 的成本将急剧 降低。进入门槛的降低会带动各行各业参与到应用环节，开发相 应的智能体也可能改变服务业态中商家与消费者的互动关系。整 体而言，本轮技术革命能够推动第三产业的蓬勃发展，我们看好 具有有效数据积累、关注服务质量提升的商社行业。 事件： AI 的摩尔定律时代可能到来，开发服务业智能体的可行性大幅提 升。DeepSeek 取得的突破标志着大模型发展从算力提升向算法优 化迈进，可预期的未来使用 AI 的成本仍将继续快速下降，经济 可行性大幅提升。AI 智能体的开发有可能实现即时性、低成本、 小型化等诸多特性，同时技术进步也会带动经济向第三产业继续 发展，带动服务业各类业态的长期成长。我们认为决定特定服务 业使用 AI 带来的提升与否主要取决于数据有效性、场景随机性 和信息对称度这三个要素。 AI 应用将助力商社消费产品、运营及流量逻辑优化重塑。餐饮酒 店等场景服务除了降本增效以外，还可以实现精准营销；旅游出 行等流程服务可以利用 ...

Investment Rating - The industry investment rating is "Increase" (maintained) [9] Core Viewpoints - The report highlights the approval of China's first CaHA facial filler, Aphranel® by Moyang Bio, which is expected to perform well in the market due to its innovative micro-sphere structure and high biocompatibility [2] - Jinbo Bio reported a significant revenue increase of 85.40% year-on-year, reaching 1.447 billion yuan, with a net profit growth of 144.65% to 733 million yuan, driven by new product development and market expansion [3][4] - The report emphasizes the long-term potential for medical aesthetics penetration to continue increasing, suggesting a focus on companies like Giant Bio, Jinbo Bio, and others in the sector [9] Summary by Sections New Product Approvals - The report discusses the approval of Aphranel® as the first CaHA injection in China, noting its superior clinical performance and safety profile [2] - Jinbo Bio launched the world's first collagen net product, targeting eye area rejuvenation through advanced technology [4] Financial Performance - Jinbo Bio's financial results for 2024 show a revenue of 1.447 billion yuan, marking an 85.40% increase, and a net profit of 733 million yuan, reflecting a 144.65% growth [3] Market Trends - The report indicates a growing trend in the medical aesthetics market, with an expectation for increased penetration rates and competitive dynamics among brands [9] - It highlights the differentiation in cosmetic channels and the competitive landscape, suggesting that leading domestic brands are likely to continue outperforming [9]

Investment Rating - The report maintains an "Add" rating for the industry [1] Core Insights - The report highlights the leading position of the company in the affordable ready-to-drink beverage sector, focusing on products priced around 6 RMB, with a total of 45,302 stores developed through a franchise model in China and Southeast Asia as of September 30, 2024 [3][10] - The global ready-to-drink beverage market is steadily growing, with China and Southeast Asia identified as key growth engines, projecting a CAGR of 7.2% from 2023 to 2028 [3][17] - The listing of the company is expected to attract additional capital into the tea beverage sector, with several major brands preparing for IPOs, indicating a growing market size [3][23] - Investment suggestions include focusing on companies like the report's subject, Gu Ming, Cha Bai Dao, and Nai Xue's Tea within the tea beverage sector [3][24] Summary by Sections 1. Industry Viewpoint - The company is positioned as a leader in the affordable ready-to-drink beverage market, with significant market share and store presence [10] 2. Market Performance Review - The report provides a performance overview of various indices, noting a decline in the retail index by 0.67% during the week [25] 3. Company Valuation Table - The report includes a valuation table for various companies, indicating their market capitalization and projected earnings [31]

Macro Analysis - The upcoming National People's Congress (NPC) is expected to maintain an economic growth target of around 5%[11] - Key focuses include boosting consumption, fiscal and monetary policy coordination, and structural reforms to improve the business environment[11] - Five major industry themes for 2025 are identified: AI and AI+, quality consumption, new urbanization, infrastructure overseas, and food security[11] Market Impact - The NPC is anticipated to establish industry trends with policies supporting AI and AI+ as the most significant trends for 2025[16] - Enhancing consumer sentiment and happiness is a core policy concern, with current consumption performance being relatively weak[16] - The transition from old to new economic drivers will take time, with price rather than volume being a key factor influencing major asset changes in 2025[16] Investment Highlights - Jiufeng Energy (605090.SH) shows steady growth in clean energy with LNG domestic sales increasing, and the company’s gross profit per ton is improving[17] - Solid growth in the traditional Chinese medicine sector is noted for Guoshengtang (02273.HK), with a CAGR of 26.2% from 2018 to 2023[21] - Ximai Food (002956.SZ) has seen a steady increase in revenue, with a 5-year CAGR of 13.1% despite profit fluctuations[24] Risk Considerations - Risks include potential underperformance of policy support, slower-than-expected economic recovery, and competition in various sectors[7][12][30]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights that the company has received approval for the first domestic Class III medical device registration for hydroxyapatite microspheres, indicating a significant advancement in its medical aesthetics strategy [6][8] - The company is expected to maintain steady growth, with projected revenues of 28.92 billion, 35.90 billion, and 42.58 billion for the years 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of 29.94%, 24.15%, and 18.60% [9][11] - The report emphasizes the company's strategic focus on the "dual beauty" strategy, which integrates beauty and health, and its proactive investments in various beauty-related sectors [8][9] Summary by Sections Investment Rating - The company maintains an "Increase" rating, indicating a favorable outlook compared to the market [2] Financial Performance - The company's main revenue is projected to grow from 17.32 billion in 2022 to 42.58 billion by 2026, with net profit increasing from 1.74 billion to 5.33 billion in the same period [7][11] - Earnings per share (EPS) are expected to rise from 0.43 in 2022 to 1.33 in 2026, reflecting a positive trend in profitability [7][11] Market Position - The report notes that the hydroxyapatite microsphere product has shown strong market demand, with a 21% year-on-year increase in treatment numbers in the U.S. in 2022 [8] - The company is expanding its product offerings in the color cosmetics sector, which is expected to serve as a new growth engine [9] Strategic Initiatives - The company is actively investing in various beauty and health-related businesses, including partnerships with firms specializing in regenerative materials and high-end beauty devices [8][9]

证券代码：603983 证券简称：丸美股份 公告编号：2024-048 广东丸美生物技术股份有限公司 控股股东及实际控制人减持计划时间届满暨 未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 截至本减持计划披露前，广东丸美生物技术股份有限公司（以下简称"公司"） 控股股东、实际控制人、董事长兼首席执行官孙怀庆先生持有公司 291,600,000 股，占公司总股本的 72.72%。 减持计划的实施结果情况 因自身资金需求，孙怀庆先生计划在 2024 年 8 月 26 日至 2024 年 11 月 25 日期间，采用集中竞价及大宗交易的方式减持公司股份数量合计不超过 12,030,000 股，不超过公司总股本的 3%。其中，通过集中竞价交易方式进行减 持的，任意连续 90 日内减持总数不超过公司股份总数的 1%；通过大宗交易方式 进行减持的，任意连续 90 日内减持总数不超过公司股份总数的 2%。详见公司于 2024 年 8 月 1 日披露的《广东丸美生物技术股份 ...

证券代码：603983 证券简称：丸美股份 公告编号：2024-034 广东丸美生物技术股份有限公司 关于 2024 年第二季度主要经营数据的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 眼部类产品平均售价上升原因： 主要系本期通过优化销售策略、加大价格管 控，爆品及新品眼膜平均售价有所提升所致。 护肤类产品平均售价上升原因： 主要系本期售价较高的重组胶原系列产品收 入占比上升以及货品结构变化拉高了平均售价所致。 主要产品 产量(支) 销量(支) 营业收入（元） 眼部类 1,601,592 1,241,058 125,338,758 护肤类 3,974,325 3,178,100 289,084,818 洁肤类 1,009,008 983,170 54,205,196 美容类 4,344,661 3,518,489 208,092,890 一、2024 年第二季度公司主要产品的产量、销量及收入实现情况 美容类产品平均售价下降原因： 主要系本期推出的促销品售价低且销量不错 拉低了平均售价所致。 （二）2024 年第二 ...

证券代码：603983 证券简称：丸美股份 公告编号：2024-030 广东丸美生物技术股份有限公司 关于控股股东部分股份解除质押的公告 2024 年 6 月 18 日 重要内容提示: ● 广东丸美生物技术股份有限公司（以下简称"公司"）控股股东孙怀庆 先生持有公司股份 291,600,000 股，占公司总股本的 72.72%；本次解除质押后， 孙怀庆先生所持公司股份不存在质押情形。 近日，公司收到控股股东孙怀庆先生的通知，获悉其已将质押的 16,670,000 股股份办理了解质手续，具体情况如下： | 股东名称 | 孙怀庆 | | --- | --- | | 本次解除质押股份 | 16,670,000 股 | | 占其所持股份比例 | 5.72% | | 占公司总股本比例 | 4.16% | | 解除质押时间 | 2024 年 6 月 14 日 | | 持股数量 | 291,600,000 股 | | 持股比例 | 72.72% | | 剩余被质押股份数量 | 0 股 | | 剩余被质押股份数量占其所持股份比例 | 0% | | 剩余被质押股份数量占公司总股本比例 | 0% | 本次解除质押后，孙怀庆先生及 ...

证券代码：603983 证券简称：丸美股份 公告编号：2024-023 广东丸美生物技术股份有限公司 关于职工代表监事换届选举的公告 本公司监事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东丸美生物技术股份有限公司（以下简称"公司"）第四届监事会任期即 将届满，根据《公司法》和《公司章程》等的有关规定，公司于 2024 年 5 月 17 日召开职工代表大会，选举陈青梅女士为公司第五届监事会职工代表监事。 经审查，陈青梅女士的任职资格和条件，符合法律、法规及规范性文件和《公 司章程》关于担任上市公司职工代表监事的规定。职工代表监事陈青梅女士将与 公司 2023 年年度股东大会选举产生的股东代表监事梁焕秋女士、陈嘉扬女士共 同组成公司第五届监事会，任期自股东大会审议通过之日起三年。 陈青梅女士，中国国籍，无境外永久居留权，1981 年 2 月出生，本科，自 2002 年加入广州佳禾化妆品有限公司（公司前身），现任公司职工代表监事、高 级财务经理。 特此公告。 广东丸美生物技术股份有限公司监事会 2024 年 5 月 18 日 ...